Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

21. Clinical benefit table: Hyalgan vs corticosteroids and other IA therapy. Continu.

Study Time Treatment Outcome (scale) N of Pts Baseline Mean End of Study Mean Absolute Benefit Relative Difference
Leardini 1987 1‐4 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 20 41.30 13.00 ‐4.5 (I) ‐13.5% (I)
    C: MPA   20 33.40 9.60    
Leardini 1991 1‐4 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 20 47.40 10.73 ‐14.0 (I) ‐32.1% (I)
    C: MPA   20 43.54 20.83    
Pietrogrande 1991 1‐4 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 45 64.89 20.00 ‐5.3 (I) ‐8.2% (I)
    C: MPA   45 64.89 25.32    
Leardini 1987 5‐13 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 20 41.30 11.20 ‐5.8 (I) ‐17.4% (I)
    C: MPA   20 33.40 9.10    
Leardini 1991 5‐13 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 20 47.40 9.48 ‐17.7 (I) ‐40.7% (I)
    C: MPA   20 43.54 23.33    
Pietrogrande 1991 5‐13 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 45 64.89 19.71 ‐7.3 (I) ‐11.3% (I)
    C: MPA   45 64.89 27.05    
Leardini 1987 45‐52 wk T: Hyalgan Pain intensity (0‐100 mm VAS) 15 41.30 20.30 ‐5.4 (I) ‐16.2% (I)
    C: MPA   17 33.40 17.80    
Leardini 1987 1‐4 wk T: Hyalgan Range of motion (flexion in degrees) 20 108.40 113.40 ‐3.2 (W) ‐3.1% (W)
    C: MPA   20 104.20 112.40    
Pietrogrande 1991 1‐4 wk T: Hyalgan Range of motion (flexion in degrees) 45 114.13 121.38 3.3 (I) 3% (I)
    C: MPA   45 108.81 112.75    
Leardini 1987 5‐13 wk T: Hyalgan Range of motion (flexion in degrees) 20 108.40 116.70 ‐1.8 (W) ‐1.7% (W)
    C: MPA   20 104.20 114.30    
Pietrogrande 1991 5‐13 wk T: Hyalgan Range of motion (flexion in degrees) 45 114.13 121.10 2.4 (I) 2.2% (I)
    C: MPA   45 108.81 113.35    
Leardini 1987 45‐52 wk T: Hyalgan Range of motion (flexion in degrees) 15 108.40 109.60 ‐2.7 (W) ‐2.6% (W)
    C: MPA   17 104.20 108.10    
Jones 1995 End of treatment T: Hyalgan Pain on nominated activity (0‐100 mm VAS) 32 77.2 56.5 ‐1.6 (I) ‐2.1% (I)
    C: Triamcinolone hexacetonide   31 75.8 56.7    
Jones 1995 End of treatment T: Hyalgan Pain at rest (0‐100 mm VAS) 32 53.2 39.9 1.4 (W) 2.5% (W)
    C: Triamcinolone hexacetonide   31 55.3 40.6    
Jones 1995 End of treatment T: Hyalgan Pain at night (0‐100 mm VAS) 32 57.8 35.9 ‐2.7 (I) ‐4.3% (I)
    C: Triamcinolone hexacetonide   31 62.2 43.0    
Jones 1995 14‐26 wk T: Hyalgan Pain on nominated activity (0‐100 mm VAS) 12 77.2 44.3 ‐11.4 (I) ‐15.0% (I)
    C: Triamcinolone hexacetonide   8 75.8 54.3    
Jones 1995 14‐26 wk T: Hyalgan Pain at rest (0‐100 mm VAS) 12 53.2 28.2 ‐18.3 (I) ‐33.1% (I)
    C: Triamcinolone hexacetonide   8 55.3 48.6    
Jones 1995 14‐26 wk T: Hyalgan Pain at night (0‐100 mm VAS) 12 57.8 15.4 ‐16.3 (I) ‐26.2% (I)
    C: Triamcinolone hexacetonide   8 62.2 36.1    
Graf 1993 (other ia therapy) End of treatment T: Hyalgan Pain (0‐30) 33 14.1 19.6 4 (I) 24.7% (I)
    C: MPAE   27 16.2 17.7    
Graf 1993 (other ia therapy) End of treatment T: Hyalgan Larson function (0‐30) 33 18.0 19.1 0.6 (I) 3.6% (I)
    C: MPAE   27 16.9 17.4    
Graf 1993 (other ia therapy) End of treatment T: Hyalgan Larson total (0‐77) 33 45.7 54.1 5.9 (I) 12.7% (I)
    C: MPAE   27 46.6 49.1    
Graf 1993 (other ia therapy) End of treatment T: Hyalgan Range of motion (0‐10) 33 8.8 9.1 0.3 (I) 3.5% (I)
    C: MPAE   27 8.7 8.7